Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab in COPD Exacerbations (Phase IIb)
2021-002045-15Phase 3Active
- Sponsor
- Genentech
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Astegolimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate and severe COPD exacerbations. Started Sep 2021; status: active.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2021-002045-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002045-15.